RIGL Rigel Pharmaceuticals

$RIGL will Raul make hint or even up guidance prior to conferences? I think too soon to change guidance numbers, but a comment like we are happy with the initial launch projections. Ahead of expectations would be nice.

$RIGL the question still remains: Who’s gonna sell these 3+ million shares in order for them to get out? Are they counting on negative sales from Vepp? 😂.. The last forcats was revised higher and still didn’t have any Vepp sales calculated in. These shorts are barely hanging on and are apparently not willing to just cut losses now. Crazy to me.

$RIGL massive covering about to happen. This is just on low volume so far. Much more pain to come for them.

$RIGL The key levels to watch include: 📈 $48.00 to $50.00 (The First Risk Line): This represents the immediate ceiling of the stock's recent local trading range. Option markets imply heavy action right up to the $50.18 mark. If buying volume pushes the price past $50.00, the smaller retail short sellers—who have tighter stop-losses and less margin wiggle room—will likely panic and cover. ⚠️ $52.24 (The 52-Week High): This is the ultimate "line in the sand" for institutional short sellers. Historically, algorithmic trading systems place massive buy-stop orders just above a stock's 52-week high to mitigate unlimited risk. If RIGL breaches $52.24, it will trigger automated market-buy orders from those algorithms. Because there are so few shares available on a daily basis, a break past this level could spark a vertical price spike.

$RIGL Each Veppanu customer taking the medication for 1 year adds a penny to annual earnings. $350K price per year minus expenses and taxes = $185K/year earnings with 18.5 million shares is .01/share earnings. 10 patients equals 10 cents in earnings 100 patients = $1.00 a share in earnings 500 patients = $5.00 EPS 1000 patients = $10 EPS

$RIGL Rigel’s outstanding shares on Schwab says 18.68 million so rounding up to 19 million getting us to a $1 billion market cap should be -$52+. My next targets will then be $1.25 and $1.5 billion by year end. Didnt check what fully diluted shares are with any options, warrants etc if any knows? Enough of this price manipulation BS from last week. It’s long overdue IMO. So let’s make some more noise if you agree. DYOR and MYODs. GLTA!

$RIGL If only all my investments could be this fun...actually, the real fun hasn't even started. Just wait for VEP sales to come in.

$RIGL I think once it hits 50, it may just blow through it into 60’s. At 53, there won’t be one share shorted in the money.

$RIGL Dino’s talk was full of great content. His words not mine-we believe Vep has a well over a billion dollar market opportunity. He laid out how the salesforce is reaching the care providers. Was strong on guidance and said that it doesn’t consider Vep which they believe is a considerable opportunity. Added more! Volume is terrible today, but this will rocket if Vep is anything like they are projecting.

$RIGL Took a position here. May have been doubled in value since last year, but it still seems very much undervalued at a EPS higher then most bios every hope to realize in their most bullish scenarios, and growing.

$RIGL great presentation by Dean, he is super bullish on the Vep launch. Nice to hear such extreme confidence, sounds like we can expect great things from Q3 earnings. No update on early sales numbers, but I’m okay with that - just means we’ll get a bigger blowout when they report earnings.

$RIGL Lol whoever did that successfully pranked the hell out of me. I jumped out of bed and sprinted to my office. My wife was positive the house was on fire or someone died. 0.3 shares traded... hilarious... now please dont do that again so I dont have an early heart attack.

$RIGL Last couple days have clearly been an accumulation of retail shares and some short covering. I think we're getting closer to something big strategically that tutes are prepping for.

$RIGL My sense here is it will continue to hover around the 40’s, maybe dip into the high 30’s again, and then start to move up again in October prior to earnings in early November. I don’t think a squeeze will happen without some catalyst from good news announced, most likely earnings and/or vep sales exceeding street expectations…so probably won’t see real movement until November. I also think they’ve subtly signaled confidence in the R289 program, and there’s potentially another rerating on the horizon if that program moves forward. We should know around the same time or a little after earnings. Knowing whether the ASH presentation is in-person or just a poster should be an early sign. Very bullish, despite short games being played in the meantime.

$RIGL Rigel confirmed today that the VEPPANU launch is on track. The drug became commercially available in August 2026, and patients started receiving it almost immediately. Rigel believes VEPPANU could eventually become its largest product, even bigger than TAVALISSE. The company sees a potential market opportunity of more than $1.X billion. Rigel estimates around 20,000 eligible patients in the relevant second- and third-line treatment setting. The company has built a dedicated commercial team to support the launch. Rigel has now achieved eight consecutive quarters of profitability. Its 2026 revenue guidance remains $285–295 million, excluding VEPPANU sales. R289 is another major upcoming catalyst, with preliminary data expected by the end of 2026. Overall, today’s update is bullish, although the first meaningful VEPPANU sales numbers could be the much bigger stock-price catalyst.

$RIGL I'm getting worried about this market so I put in a 500 share sell order at 46 earlier today. They brought it back up and took those shares, then dropped it again. Might be meaningless, but it looks like they're trying to get retail to sell as they accumulate. NFA

$RIGL probably a good time to get out. This bastard will be now stuck at 45 for the next five years

$RIGL Dean Schorno exercised options to acquire 4,600 Rigel shares and retained them, according to the filing. This Form 4 reports no open-market sale. The official filing shows: September 2, 2026: 4,600 shares acquired at exercise prices ranging from $12.70 to $24.20. He subsequently directly owned 82,962 shares. Separately, 928 shares were withheld on September 1 to cover taxes. Source: SEC Form 4⁠� The $123,171 in the headline is not the purchase amount: the total exercise cost was approximately $99,924. The quoted figure appears to represent the calculated gain on the options at a share price of $48.50. My interpretation: retaining the shares may be viewed positively, but this transaction does not prove that a takeover or major announcement is imminent.

$RIGL This is a very old topic. Maybe Raul is discussing the sale of the company? A merger or some kind of deal? That might be why he’s tied up and can’t speak publicly. Is that possible?

$RIGL RIGL’s borrow fee will likely only rise significantly once shares available to borrow become scarce and demand from short sellers remains high.